Valeria Magarotto

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

Sandy Amorim, Anastasios Stathis, Mary Gleeson et al. · The Lancet Haematology · 2016 · 420 citations

Hematological Malignancy, Lymphoid Neoplasia, Translational Medicine +9

Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial

Antonio Palumbo, Michèle Cavo, Elena Zamagni et al. · Journal of Clinical Oncology · 2011 · 320 citations · Full text

Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial

Francesca Gay, Stefania Oliva, Maria Teresa Petrucci et al. · The Lancet Oncology · 2015 · 312 citations · Full text

Hematological Malignancy, Transplantation, Marrow Transplantation +12

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival

Antonio Palumbo, Sara Bringhen, Alessandra Larocca et al. · Journal of Clinical Oncology · 2014 · 210 citations · Full text

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

Monika Engelhardt, Evangelos Terpos, Martina Kleber et al. · Haematologica · 2014 · 209 citations · Full text

Immunology, Immunotherapy, Myeloid Neoplasia +17